A placebo-controlled, three-site, 200+ patient NIH-funded clinical trial which was principally concerned with possible neurocognitive improvements, was conducted between 1990 and 1995. It was found that the effect of Peptide T was not significantly different from that of placebo on the primary end points of the study - various aspects of brain function. However, Peptide T was associated with improved performance (memory and learning) in the subgroup of patients with more severe cognitive impairment.[7] A long-delayed analysis of antiviral effects from the NIH study showed peripheral viral load (combined plasma and serum) was significantly reduced in the DAPTA-treated group.[8] An eleven-person study of Peptide T effects on cellular viral load showed reductions in infected monocyte reservoir to undetectable levels in most of the patients.[9] Pert was developing orally active peptide anti-inflammatory treatments for pain and Alzheimer's Disease and studies for treatment of HIV persistent viral reservoirs.